National Infusion Center Association
“NIH COVID-19 Treatment Guidelines Strongly Recommend Use of REGEN-COV™ (casirivimab with imdevimab) in Outpatients at High Risk of Clinical Progression” This article mentions that under the […]
“High-Risk Patients with COVID-19: Outpatient Management to Prevent Progression Online Live CME Accredited Webinars” This article mentions NICA as a key resource for clinicians looking to […]
“COVID antibody treatments going unused in WA state as hospitals fill up, DOH says” As pandemic-related hospitalizations increase as a result of the Delta-variant of COVID-19, […]
By: Tiffani Bouchard, CCS Managing JW and JZ Modifiers When Billing Single-Dose Drugs Managing JW and JZ modifiers when billing single-dose drugs can be challenging. As […]
By: Pamela McIntyre, CRNI, IgCN, OCN, and VA-BC Maximizing Efficiency in Ambulatory Infusion Centers When it comes to maximizing efficiency in ambulatory infusion centers, one of […]
By: Michael Rigas, Pharm.D., FNHIA Biosimilars are also known as follow-on biologics or subsequent-entry biologics. They are FDA-approved copies of the original “innovator” drug product that […]
By: Ty Bello, BS, RCC The objective of this article is to provide information with application so you, as an Independent Ambulatory Infusion Center, can either […]
By: Kay Coulter, RN, CRNI, VA-BC In the insurance industry there’s a saying about how you don’t know you’re facing litigation until it’s too late. Ambulatory […]
What’s behind the recent surge of investments into the infusion industry? The ambulatory infusion center (AIC) industry has seen a significant surge in investment in recent […]
